HEFT Repository

Availability and use of molecular microbiological and immunological tests for the diagnosis of tuberculosis in europe

Tebruegge, Marc and Ritz, Nicole and Koetz, Karsten and Noguera-Julian, Antoni and Seddon, James A and Welch, Steven B and Tsolia, Maria and Kampmann, Beate (2014) Availability and use of molecular microbiological and immunological tests for the diagnosis of tuberculosis in europe. PloS one, 9 (6). e99129. ISSN 1932-6203.

[img]
Preview
Text
Availability and Use of Molecular Microbiological and.pdf

Download (782kB) | Preview
Official URL: http://www.plosone.org/article/info%3Adoi%2F10.137...

Abstract

INTRODUCTION

Currently only limited data exist regarding the availability and clinical use of molecular and immunological tests for tuberculosis (TB) in the European setting.

METHODS

Web-based survey of Paediatric-Tuberculosis-Network-European-Trialsgroup (ptbnet) and Tuberculosis-Network-European-Trialsgroup (TBnet) members conducted June to December 2013. Both networks comprise clinicians, microbiologists, epidemiologists and researchers predominately based in Europe.

RESULTS

191 healthcare professionals from 31 European countries participated. Overall, 26.8% of respondents did not have access to the Xpert MTB/RIF assay; only 44.6% had access to the assay in-house. However, a substantial proportion had access to other commercial and/or non-commercial PCR-based assays for TB (68.8% and 31.8%, respectively). Only 6.4% did not have access to any PCR-based assays for TB. A large proportion of participants with access to the Xpert MTB/RIF assay had used it for the analysis of non-respiratory samples [pleural fluid: 36.5%, gastric aspirates: 34.7%, cerebrospinal fluid: 34.7%, stool samples: 4.3%, blood/serum: 2.6%, 'other samples' (which included biopsy/tissue samples, lymph node aspirates, joint aspirates and urine samples): 16.5%]. Regarding interferon-gamma release assays, a greater proportion of respondents had access to the QuantiFERON-TB Gold assay (84.7%) than to the T-SPOT.TB assay (52.2%).

CONCLUSIONS

Both immunological and molecular TB tests are widely available across Europe. The QuantiFERON-TB Gold assay is more widely used than the T-SPOT.TB assay, which may reflect the difficulties of integrating an ELISPOT assay into the routine laboratory setting. Although Xpert MTB/RIF assays are optimised and solely licensed for the analysis of sputum samples, in clinical practice they are commonly used for non-respiratory samples. Further research is needed to establish how current molecular TB tests impact on patient care and outcome in the routine clinical setting.

Item Type: Article
Subjects: QW Microbiology. Immunology
WF Respiratory system. Respiratory medicine
Divisions: Planned IP Care > Respiratory Medicine
Related URLs:
Depositing User: Sophie Rollason
Date Deposited: 09 Jul 2014 08:41
Last Modified: 09 Jul 2014 08:41
URI: http://www.repository.heartofengland.nhs.uk/id/eprint/589

Actions (login required)

View Item View Item